Drug Profile
SB 509
Alternative Names: hVEGF-A; SB-509; VEGF activator zinc finger proteinLatest Information Update: 12 Jan 2017
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Class Gene therapies; Neuroprotectants; Zinc finger DNA binding proteins
- Mechanism of Action Gene transference; Genetic transcription stimulants; Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Brain injuries; Diabetic neuropathies; Spinal cord injuries; Stroke
Most Recent Events
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 03 Oct 2011 Discontinued - Phase-II for Amyotrophic lateral sclerosis in USA (IM)
- 03 Oct 2011 Discontinued - Phase-II for Diabetic neuropathies in USA (IM)